Cargando…
Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
Multiple myeloma (MM) remains an incurable disease despite improvements to available treatments and efforts to identify new drug targets. Consequently new approaches are urgently required. We have investigated the potential of native tumour necrosis factor-related apoptosis-inducing ligand (TRAIL),...
Autores principales: | Vitovski, Srdjan, Chantry, Andrew D., Lawson, Michelle A., Croucher, Peter I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353958/ https://www.ncbi.nlm.nih.gov/pubmed/22615740 http://dx.doi.org/10.1371/journal.pone.0035830 |
Ejemplares similares
-
ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
por: Lath, Darren L., et al.
Publicado: (2018) -
The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma
por: Stewart, Georgia, et al.
Publicado: (2021) -
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011) -
An added dimension to tumour TRAIL sensitivity
por: Healy, Sandra, et al.
Publicado: (2015) -
Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)